-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$9.6769.95% Upside
Design Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Design Therapeutics, Inc.?
Design Therapeutics, Inc. has been rated by research analysts at Piper Sandler, RBC Capital, Goldman Sachs in the past 90 days.